Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Digestive System | 2 | 2002 | 14 | 0.380 |
Why?
|
| Inhalation | 2 | 2002 | 5 | 0.250 |
Why?
|
| Pneumonia, Aspiration | 2 | 2002 | 7 | 0.240 |
Why?
|
| Pancreatitis | 2 | 2002 | 20 | 0.230 |
Why?
|
| Diarrhea | 2 | 2006 | 32 | 0.200 |
Why?
|
| Digestive System Diseases | 1 | 2002 | 5 | 0.200 |
Why?
|
| Celiac Disease | 1 | 2002 | 7 | 0.190 |
Why?
|
| Enteral Nutrition | 2 | 2002 | 62 | 0.180 |
Why?
|
| Crohn Disease | 1 | 2002 | 38 | 0.180 |
Why?
|
| Food Hypersensitivity | 3 | 2014 | 40 | 0.170 |
Why?
|
| Colonoscopy | 1 | 2021 | 71 | 0.160 |
Why?
|
| Adenoma | 1 | 2021 | 61 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2014 | 81 | 0.160 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 155 | 0.150 |
Why?
|
| Anion Exchange Resins | 1 | 1998 | 2 | 0.140 |
Why?
|
| Colestipol | 1 | 1998 | 2 | 0.140 |
Why?
|
| Bile Acids and Salts | 1 | 1998 | 7 | 0.140 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 3 | 0.110 |
Why?
|
| Hepatitis B | 1 | 2014 | 12 | 0.110 |
Why?
|
| Vaccination | 1 | 2014 | 26 | 0.110 |
Why?
|
| Toll-Like Receptors | 1 | 2014 | 17 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 50 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2014 | 70 | 0.110 |
Why?
|
| Cathartics | 1 | 2013 | 6 | 0.110 |
Why?
|
| Mannans | 1 | 2013 | 17 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 98 | 0.100 |
Why?
|
| Weight Loss | 1 | 2013 | 122 | 0.100 |
Why?
|
| Obesity | 1 | 2013 | 293 | 0.090 |
Why?
|
| Humans | 13 | 2021 | 23331 | 0.080 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2008 | 9 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2008 | 46 | 0.070 |
Why?
|
| Fermentation | 1 | 2007 | 13 | 0.070 |
Why?
|
| Dietary Fiber | 1 | 2007 | 25 | 0.060 |
Why?
|
| Middle Aged | 6 | 2014 | 8055 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 56 | 0.060 |
Why?
|
| Enterocolitis | 1 | 2006 | 4 | 0.060 |
Why?
|
| Mastocytosis, Systemic | 1 | 2006 | 7 | 0.060 |
Why?
|
| Mast Cells | 1 | 2006 | 18 | 0.060 |
Why?
|
| Acute Disease | 2 | 2002 | 168 | 0.060 |
Why?
|
| Adult | 6 | 2014 | 7070 | 0.050 |
Why?
|
| Aged | 5 | 2014 | 7552 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 1038 | 0.050 |
Why?
|
| Gastric Acid | 1 | 2002 | 9 | 0.050 |
Why?
|
| Permeability | 1 | 2002 | 94 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2002 | 130 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2002 | 33 | 0.050 |
Why?
|
| Critical Illness | 1 | 2002 | 110 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 85 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 192 | 0.040 |
Why?
|
| Female | 6 | 2014 | 13124 | 0.040 |
Why?
|
| Male | 5 | 2014 | 12629 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 1916 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 594 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 442 | 0.040 |
Why?
|
| Feces | 1 | 1998 | 80 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1998 | 382 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 5 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 8 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 29 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 66 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2014 | 81 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2013 | 55 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 123 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 246 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 64 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2013 | 129 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 384 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 233 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 487 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 774 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 819 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 384 | 0.020 |
Why?
|
| Gastrointestinal Motility | 2 | 2007 | 13 | 0.020 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1990 | 3 | 0.020 |
Why?
|
| Erythromycin | 1 | 1990 | 4 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 1674 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2006 | 389 | 0.020 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2008 | 5 | 0.020 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2008 | 6 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 226 | 0.020 |
Why?
|
| Fatty Acids, Volatile | 1 | 2007 | 26 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 3040 | 0.020 |
Why?
|
| Ranitidine | 1 | 2006 | 3 | 0.020 |
Why?
|
| Cetirizine | 1 | 2006 | 3 | 0.020 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2006 | 3 | 0.020 |
Why?
|
| Tryptases | 1 | 2006 | 5 | 0.020 |
Why?
|
| Duodenum | 1 | 2006 | 5 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2006 | 14 | 0.020 |
Why?
|
| Cell Count | 1 | 2006 | 71 | 0.020 |
Why?
|
| Asthma | 1 | 2008 | 150 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 161 | 0.010 |
Why?
|
| Colon | 1 | 2006 | 110 | 0.010 |
Why?
|
| Depression | 1 | 2008 | 369 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 1523 | 0.010 |
Why?
|
| North America | 1 | 2002 | 32 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 1998 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 452 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 486 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 578 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 740 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 3783 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 3287 | 0.010 |
Why?
|
| Child | 1 | 2002 | 1171 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 2988 | 0.010 |
Why?
|